Leerink Partnrs Reiterates Outperform Rating for Immunome (NASDAQ:IMNM)

Immunome (NASDAQ:IMNMGet Free Report)‘s stock had its “outperform” rating reiterated by stock analysts at Leerink Partnrs in a research report issued on Monday, PriceTargets.com reports. Leerink Partnrs also issued estimates for Immunome’s Q4 2023 earnings at ($0.25) EPS, FY2023 earnings at ($0.50) EPS, Q1 2024 earnings at ($1.05) EPS, Q2 2024 earnings at ($0.12) EPS, Q3 2024 earnings at ($0.15) EPS, Q4 2024 earnings at ($0.18) EPS, FY2024 earnings at ($1.50) EPS, FY2025 earnings at ($1.36) EPS and FY2026 earnings at ($1.44) EPS.

Several other analysts have also recently commented on IMNM. SVB Leerink initiated coverage on shares of Immunome in a research note on Monday. They set an “outperform” rating and a $30.00 price target on the stock. Wedbush increased their price target on shares of Immunome from $12.00 to $19.00 and gave the company an “outperform” rating in a research note on Tuesday, January 23rd. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome has an average rating of “Buy” and a consensus price target of $19.00.

Check Out Our Latest Research Report on Immunome

Immunome Trading Down 4.1 %

NASDAQ IMNM opened at $18.50 on Monday. The firm has a market cap of $790.51 million, a price-to-earnings ratio of -10.22 and a beta of 1.53. The company has a 50 day moving average of $10.69 and a 200-day moving average of $8.72. Immunome has a 1-year low of $4.04 and a 1-year high of $19.49.

Immunome (NASDAQ:IMNMGet Free Report) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.36) earnings per share for the quarter. The firm had revenue of $3.57 million for the quarter. On average, analysts forecast that Immunome will post -1.21 earnings per share for the current year.

Hedge Funds Weigh In On Immunome

A number of hedge funds and other institutional investors have recently bought and sold shares of IMNM. Point72 Asset Management L.P. bought a new position in Immunome in the second quarter valued at approximately $3,307,000. TD Asset Management Inc bought a new position in Immunome in the third quarter valued at approximately $1,063,000. Bank of Montreal Can bought a new position in shares of Immunome during the second quarter worth $800,000. Cerity Partners LLC bought a new position in shares of Immunome during the fourth quarter worth $656,000. Finally, Emfo LLC bought a new position in shares of Immunome during the fourth quarter worth $633,000. 37.76% of the stock is owned by institutional investors.

Immunome Company Profile

(Get Free Report)

Immunome, Inc, a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.

See Also

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.